億勝生物科技(01061.HK)以9,700萬人幣向百盛藥業收購產品權益
億勝生物科技(01061.HK)公布,附屬珠海億勝與華邦生命(002004.SZ)旗下百盛藥業就可能收購事項訂立產品權益轉讓協議,以代價9,700萬元人民幣向百盛藥業收購產品「適麗順」的權益,其中包括相關知識產權、技術及工藝,以及其他有關權益(包括合約權益)及其MAH。
「適麗順」已於2010年獲得批准,可用於治療中心性漿液性脈絡膜視網膜病變、中心性滲出性脈絡膜視網膜病變、玻璃體出血、玻璃體混濁及視網膜中央靜脈阻塞等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.